FDA Approves New Treatment Regimen for Individuals Receiving Keytruda (pembrolizumab) for Resectable Non-Small Cell Lung Cancer
October 18, 2023
On October 16, 2023, the U.S. Food and Drug Administration (FDA) approved a new treatment plan for people receiving Keytruda (pembrolizumab) for resectable non-small cell lung cancer (NSCLC). This approval is based on results from the KEYNOTE-671 (NCT03425643) clinical trial that assessed a new treatment plan for persons with resectable stage II (2), IIIA (3A), or IIIB (3B) NSCLC.Individuals received Keytruda (pembrolizumab) with platinum-based chemotherapy prior to surgery (neoadjuvant treatment), followed by treatment with Keytruda (pembrolizumab) alone post-surgery (adjuvant treatment). Results showed that people given this treatment regimen showed a clinically meaningful benefit, including a longer period of time before progression or recurrence, compared to individuals who received only pre-operative platinum-based chemotherapy.Read the full announcement from the FDA here.
Lung cancer questions? Contact our free HelpLine at support@go2.org or 1-800-298-2436.